Skip to main content
logo
BioInfra Co., Ltd. (KOSDAQ:199730)
South Korea flag South Korea · Delayed Price · Currency is KRW
1,580.00
-54.00 (-3.30%)
At close: Jul 20, 2026

Revenue by Segment

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
Phase 1 Clinical Trial
12.46B
Bioequivalence Testing
9.76B
Clinical / Non-clinical Sample Analysis
1.19B
Sample Analysis for Not Licensing Purposes, etc.
325.77M
Non-approved Clinical Trials
34.71M
Clinical Trials for Approval
22.01M
Other
36.94M

Revenue by Geography

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024FY 2023FY 2022FY 2021FY 2020
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
South Korea
23.83B
South Korea Growth
-20.90%